F6937
FluoroShield™
liquid, with 1,4-Diazabicyclo[2.2.2]octane
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12171500
NACRES:
NA.47
Product Name
Fluoroshield™ with 1,4-Diazabicyclo[2.2.2]octane, liquid
form
liquid
Quality Level
technique(s)
immunofluorescence: suitable
pH range
8.0-8.4
application(s)
diagnostic assay manufacturing
hematology
histology
storage temp.
2-8°C
General description
Fluoroshield™ with 1,4-Diazabicyclo[2.2.2]octane is an aqueous mounting medium for preserving the fluorescence of tissue and cell smears.
Application
Fluoroshield™ with 1,4-Diazabicyclo[2.2.2]octane prevents rapid photobleaching of FITC, Texas Red®, AMCA, ALEXA FLUOR™ 488, ALEXA FLUOR 594, Cy® dyes, and tetramethylrhodamine.
Biochem/physiol Actions
Fluoroshield™ with 1,4-Diazabicyclo[2.2.2]octane mounting medium is fortified with 1,4-Diazabicyclo[2.2.2]octane (a generic version of DABCO®), an anti-fade reagent used to retard photobleaching of fluorescein and other fluorescent dyes.
Legal Information
ALEXA FLUOR is a trademark of Life Technologies
Cy is a registered trademark of Cytiva
DABCO is a registered trademark of Air Products & Chemicals, Inc.
FluoroShield is a trademark of ImmunoBioScience Corp.
Texas Red is a registered trademark of Life Technologies
Still not finding the right product?
Explore all of our products under Fluoroshield™ with 1,4-Diazabicyclo[2.2.2]octane
signalword
Danger
hcodes
Hazard Classifications
Eye Dam. 1
Storage Class
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Morphological changes of cortical and hippocampal neurons after treatment with VEGF and bevacizumab.
Latzer P, et al.
CNS Neuroscience & Therapeutics, 22(6), 440-450 (2016)
Anna Wolters et al.
Neural regeneration research, 16(11), 2243-2249 (2021-04-06)
One of the major challenges in emergency medicine is out-of-hospital cardiac arrest (OHCA). Every year, about 53-62/100 000 people worldwide suffer an out-of-hospital cardiac arrest with serious consequences, whereas persistent brain injury is a major cause of morbidity and mortality
Mariana L Casalia et al.
Annals of neurology, 82(4), 530-542 (2017-08-24)
A significant proportion of the more than 50 million people worldwide currently suffering with epilepsy are resistant to antiepileptic drugs (AEDs). As an alternative to AEDs, novel therapies based on cell transplantation offer an opportunity for long-lasting modification of epileptic
Global Trade Item Number
| SKU | GTIN |
|---|---|
| F6937-20ML | 04061838105356 |